1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 3:Accuracy for brain tumor characterization on MR images acquired after administration of 0.1-mmol/kg gadoteridol or 0.1-mmol/kg gadobutrol in 128 patients with 246 histologically confirmed brain tumors
Lesion Characterization Reader 1 Reader 2 Reader 3 Gadoteridol Gadobutrol Gadoteridol Gadobutrol Gadoteridol Gadobutrol No. patients with tumors correctly characterized at MRI 94 (73.4%) 96 (75.0%) 106 (82.8%) 101 (78.9%) 93 (72.7%) 83 (64.8%) P value (95% CI of difference, %) .695 (−9.4 to 6.2) .132 (−1.1 to 8.9) .012 (1.8 to 13.8) No. tumors correctly characterized at MRI 169 (68.7%) 164 (66.7%) 198 (80.5%) 188 (76.4%) 166 (67.5%) 148 (60.2%) P value (95% CI of difference, %) .492 (−3.8 to 7.8) .059 (−0.1 to 8.3) .001 (3.0 to 11.6)